NEW YORK, March 5 - Ciphergen Biosystems and Beckman Coulter on Tuesday said they plan to automate clinical proteomics research.

Terms of the agreement call for Ciphergen to combine its SELDI protein chip biomarker system with a custom version of Beckman's Biomek 2000 system. The resulting "turnkey" platform will be marketed to industry, academia, and government institutes, the companies said. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The US National Institutes of Health and the Food and Drug Administration have proposed changing gene therapy oversight, the Associated Press reports.

Nature News reports that the Salk Institute has asked for the scope of a gender discrimination lawsuit brought against it to be narrowed.

CNBC reports that the sequencing startup Veritas aims to sequence individuals who fall at extremes.

In PLOS this week: genotyping of indigenous North African goats, program to simulate evolve and resequencing studies, and more.